Results 141 to 150 of about 11,074 (164)

High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors. [PDF]

Clin Lung Cancer
Nie Y, Staley A, Hinz TK, Perez-Johnston R, Merrick DT, Yang MC, Davies KD, Bunn PA, Aisner DL, Camidge DR, Schenk EL, Heasley LE, Patil T.   +12 more
europepmc   +1 more source

A Patient With Novel <i>PPP1CB</i> <i>-ALK</i> Fusion Advanced NSCLC Achieved Long Survival From Alectinib: A Case Report. [PDF]

JTO Clin Res Rep
Jin C, Li C, Zhang T, Qiu J, Guo M, He Z, Wu D.   +6 more
europepmc   +1 more source

Which evolutionary game-theoretic model best captures NSCLC dynamics? [PDF]

PLoS One
Garjani H, Dubbeldam J, Staňková K, Brown JS.   +3 more
europepmc   +1 more source

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up. [PDF]

Cardio-Oncology, 2023
Background: Anaplastic lymphoma kinase (ALK) translocations in metastatic non-small cell lung cancer (3% to 7%) predict for response to ALK-inhibitors (eg, alectinib, first line), resulting in a 5-year survival rate of ∼60% and median progression-free ...
Mathijssen Ron, Anne-Marie Dingemans, Ron van Schaik   +2 more
exaly   +3 more sources

Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib

ESMO Open, 2022
Alectinib is a preferred first-line therapy for patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) in several national clinical practice guidelines.
Rafal Dziadziuszko, Solange Peters, V Smoljanovic   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease

Journal of Oncology Pharmacy Practice, 2021
Heng-Sheng Chao, Jhong-Ru Huang, Chung-Wei Chou   +2 more
exaly  

Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer

Journal of Thoracic Oncology, 2023
Simon de Leeuw, G D Marijn Veerman
exaly  

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer☆

ESMO Open, 2022
Y Takiguchi, H Nokihara, T Kozuki
exaly